摘要
目的探讨瑞舒伐他汀钙联合依折麦布在老年冠心病合并高脂血症患者中的应用效果.方法选取2021年2月—2022年11月我院收治的94例冠心病合并高脂血症患者为研究对象,按随机数字表法分为两组,每组47例.两组均采用常规治疗,在此基础上,对照组采用瑞舒伐他汀钙治疗,观察组采用瑞舒伐他汀钙联合依折麦布治疗,均持续3个疗程.对比两组患者的临床疗效、血脂水平、心功能指标、颈动脉情况及不良反应发生率.结果观察组的治疗总有效率为95.74%,高于对照组的80.85%,差异有统计学意义(P<0.05).治疗后,观察组的甘油三酯、低密度脂蛋白、总胆固醇水平分别为(1.83±0.25)mmol/L、(1.80±0.27)mmol/L、(4.67±0.72)mmol/L,均低于对照组,高密度脂蛋白水平为(1.50±0.24)mmol/L,高于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的左心室舒张末期内径、左心室收缩末期内径分别为(46.48±3.11)mm、(42.10±4.09)mm,均短于对照组,左室射血分数为(47.56±4.62)%,高于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的颈动脉内膜-中膜厚度为(1.18±0.30)mm,薄于对照组,斑块面积为(0.045±0.014)cm2,小于对照组,组间差异有统计学意义(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论采用瑞舒伐他汀钙联合依折麦布治疗冠心病合并高脂血症的效果显著,可纠正患者血脂异常,改善其心功能,安全性高,值得临床推广使用.
Objective To investigate the effect of rosuvastatin calcium combined with ezetimibe in elderly patients with coronary heart disease complicated with hyperlipidemia.Methods 94 patients with coronary heart disease complicated with hyperlipidemia admitted to the hospital from February 2021 to November 2022 were selected as the research objects and were divided into two groups according to random number table method,with 47 cases in each group.Both groups received conventional treatment.On this basis,the control group was treated with rosuvastatin calcium,and the observation group was treated with rosuvastatin calcium combined with ezetimibe.Both groups were treated continuously for 3 courses.The clinical efficacy,blood lipid levels,cardiac function indexes,carotid artery condition and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.74%,higher than 80.85%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of triglyceride,low density lipoprotein and total cholesterol in the observation group were(1.83±0.25)mmol/L,(1.80±0.27)mmol/L and(4.67±0.72)mmol/L,respectively,which were lower than those in the control group,and the level of high density lipoprotein was(1.50±0.24)mmol/L,which was higher than that in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the left ventricular end-diastolic diameter and left ventricular end-systolic diameter of the observation group were(46.48±3.11)mm and(42.10±4.09)mm,respectively,which were shorter than those of the control group,and the left ventricular ejection fraction was(47.56±4.62)%,higher than that of the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the carotid intima-media thickness in the observation group was(1.18±0.30)mm,which was thinner than that in the control group,and the plaque area was(0.045±0.014)cm2,which was smaller than that in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Rosuvastatin calcium combined with ezetimibe is effective in the treatment of coronary heart disease complicated with hyperlipidemia,which can correct dyslipidemia and improve cardiac function.It is safe and worthy of clinical promotion.
作者
荆树贞
JING Shuzhen(Department of Internal Medicine,Dongying Shengli Shengdong Hospital,Dongying Shandong,257055,China)
出处
《反射疗法与康复医学》
2023年第8期134-137,共4页
Reflexology And Rehabilitation Medicine
关键词
冠心病
高血脂症
依折麦布
瑞舒伐他汀钙
血脂水平
心功能
不良反应
Coronary heart disease
Hyperlipidemia
Ezetimibe
Rosuvastatin calcium
Blood lipid levels
Cardiac function
Adverse reactions
作者简介
荆树贞(1976-),女,山东东营人,本科,主治医师,研究方向:内科常见老年疾病诊治。
